Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery.

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

February 1, 2026

Study Completion Date

May 1, 2027

Conditions
Morbid Obesity Requiring Bariatric SurgeryPostoperative PainPostoperative Pain ManagementPostoperative AnalgesiaPostoperative Adjuvant TreatmentPostoperative Inflammatory MarkersPostoperative Inflammatory Response
Interventions
DRUG

Intravenous Lidocaine infusion + Standard Anesthesia

Continuous IV infusion of lidocaine 1 % (10 mg mL-¹) at 0.3 mL kg-¹ h-¹ (≈ 1.5 mg kg-¹ h-¹) from induction of anaesthesia to skin closure. No loading bolus, no post-operative infusion.

DRUG

Intravenous Dexmedetomidine infusion + Standard Anesthesia

Continuous IV infusion of dexmedetomidine 1 µg mL-¹ at 0.3 mL kg-¹ h-¹ (≈ 0.3 µg kg-¹ h-¹) without loading dose, started after induction and stopped at skin closure. No post-operative infusion.

DRUG

Lidocaine + Dexmedetomidine Combination (LIDEX) + Standard Anesthesia

Single syringe containing lidocaine 1 % (10 mg mL-¹) + dexmedetomidine 1 µg mL-¹, infused IV at 0.3 mL kg-¹ h-¹ (delivering ≈ 1.5 mg kg-¹ h-¹ lidocaine + 0.3 µg kg-¹ h-¹ dexmedetomidine) from induction to skin closure.

DRUG

0.9 % Saline Placebo + Standard Anesthesia

Volume-matched IV infusion of 0.9 % normal saline at 0.3 mL kg-¹ h-¹ for the same duration and through the same delivery line as active arms; identical syringe appearance.

Trial Locations (1)

06720

Unidad Médica de Alta Especialidad Hospital de Especialidades del Centro Médico Nacional Siglo XXI, Mexico City

All Listed Sponsors
lead

Instituto Mexicano del Seguro Social

OTHER_GOV

NCT07073846 - Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery. | Biotech Hunter | Biotech Hunter